AI Article Synopsis
- * A study reported three cases of metastatic PDAC patients with wildtype KRAS, who had rare pathogenic alterations in BRAF or RET and received targeted therapy with varying results.
- * The authors suggest that these cases highlight the need for more research and clinical trials focused on this small but important population of PDAC patients with uncommon driver mutations.
Article Abstract
Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof-of-concept cases argue in favor of additional research and clinical trials' effort in this small but significant PDAC population with uncommon driver mutations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381925 | PMC |
| http://dx.doi.org/10.1159/000496018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!